pRb controls Estrogen Receptor alpha protein stability and activity

Isabella Caligiuri; Giuseppe Toffoli; Antonio Giordano; Flavio Rizzolio

doi:10.18632/oncotarget.1036

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

pRb controls Estrogen Receptor alpha protein stability and activity

Isabella Caligiuri, Giuseppe Toffoli, Antonio Giordano _ and Flavio Rizzolio

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2013; 4:875-883. https://doi.org/10.18632/oncotarget.1036

Metrics: PDF 2714 views | HTML 3455 views | ?

Abstract

Isabella Caligiuri1,2,3, Giuseppe Toffoli3, Antonio Giordano1,2, and Flavio Rizzolio1,3

1 Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA

2 Department of Medicine, Surgery and Neuroscience, University of Siena, Siena Italy

3 Division of Experimental and Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, Aviano (PN)

Correspondence:

Antonio Giordano , email:

Flavio Rizzolio, email:

Keywords: pRb, Estrogen receptor alpha, proteasome, chaperone proteins, breast cancer

Received: May 15, 2013, Accepted: May 31, 2013, Published: June 3, 2013

Abstract

A cross talk between the Estrogen Receptor (ESR1) and the Retinoblastoma (pRb) pathway has been demonstrated to influence the therapeutic response of breast cancer patients but the full mechanism remains poorly understood. Here we show that the N-terminal domain of pRb interacts with the CD domain of ESR1 to allow for the assembly of intermediate complex chaperone proteins HSP90 and p23. We demonstrated that a loss of pRb in human/mouse breast cells decreases the expression of the ESR1 protein through the proteasome pathway. Our work reveals a novel regulatory mechanism of ESR1 basal turnover and activity and an unanticipated relationship with the pRb tumor suppressor.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 1036

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

pRb controls Estrogen Receptor alpha protein stability and activity

Abstract